

# Pharmacy and Therapeutics Committee

October 16, 2019 12:00pm -5:00 pm  
 Gold Room, 3rd Floor - 701 E. Jefferson Phoenix, AZ 85034

Teleconference: 530-500-4054 Passcode: 434924#

Time	Topic
12:00 PM	<b>Welcome and Introductions:</b> Sara Salek, MD, Chief Medical Officer, AHCCCS <ul style="list-style-type: none"> <li>• May 23, 2019 - P&amp;T Minutes Review and Vote</li> </ul>
12:15 PM	<b>Conflict of Interest Training:</b> Robert L. Ellman, Ellman Law Group LLC
12:45 PM	<b>Non-Supplemental Rebate Class Review:</b> Clinical review by Hind Douiki, PharmD, Magellan <ol style="list-style-type: none"> <li>1. Antifungal – Oral Agents               <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>2. Antifungal – Topicals               <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>3. Antimigraine Agents - Triptans               <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>4. Beta Blockers               <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>5. BPH Treatments               <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>6. Calcium Channel Blockers               <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>7. Leukotriene Modifiers               <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>8. Phosphate Binders               <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>9. Sedative Hypnotics               <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> <li>10. Topical Steroids- Low, Medium, High &amp; Very High Potency               <ol style="list-style-type: none"> <li>a. Public Testimony: None</li> </ol> </li> </ol>

<b>2:30 PM</b>	<b>New Drug Reviews: Hind Douiki, PharmD – Magellan</b> <ul style="list-style-type: none"> <li>• Mayzent – Siponimod</li> <li>• Rocklatan – Netarsudil and Latanoprost</li> <li>• Mavenclad – Cladribine</li> <li>• Evenity – Romosozumab-aqqg</li> <li>• Diacomit – Stiripentol</li> <li>• Skyrizi – Risankizumab</li> <li>• Cutaquig – Immune Globulin</li> <li>• Egaten – Triclabendazole</li> <li>• Sunosi – Solriamfetol</li> <li>• Rinvoq – Upadacitinib</li> <li>• Vyndamax – Tafamidis</li> </ul>
<b>3:00 PM</b>	<b>Break &amp; Executive Session</b>
<b>4:00 PM</b>	<b>Public Therapeutic Class Votes</b>
<b>4:30 PM</b>	<b>Biosimilar Update:</b> <ul style="list-style-type: none"> <li>• <b>Herceptin</b> <ul style="list-style-type: none"> <li>○ Herzuma (trastuzumab-pkrb): FDA approved December 2018; anticipated availability is currently unknown</li> <li>○ Ogivri (trastuzumab-dkst): FDA approved December 2017; anticipated availability is currently unknown</li> <li>○ Ontruzant (trastuzumab-dttb): FDA approved January 2019; availability anticipated in June 2019</li> <li>○ Trazimera (trastuzumab-qyyp): FDA approved March 2019; anticipated availability is currently unknown</li> <li>○ Kanjinti (Trastuzumab-Anns): available</li> </ul> </li> <li>• <b>Avastin</b> <ul style="list-style-type: none"> <li>○ Zirabev (bevacizumab-bvzr): FDA approved June 2019; anticipated availability is currently unknown</li> <li>○ Mvasi (Bevacizumab-awwb): available</li> </ul> </li> </ul>
<b>5:00 PM</b>	<b>Meeting Adjournment</b> <b>Meeting Dates: January 22, 2020 &amp; May 19, 2020</b>